Minovia is a clinical stage company focused on the development and application of mitochondrial cell therapies for patients suffering mitochondrial dysfunction. Mitochondrial Augmentation Technology (MAT) is a cell therapy platform where an off-the-shelf allogeneic isolated mitochondria are developed as cryopreserved, healthy and functional, energy producing organelles and used to augment various cell types to be used as therapeutics products. The lead product, MNV-201 consists of autologous hematopoietic stem and progenitor cells (HSPCs) augmented ex vivo with healthy mitochondria. MNV-201 is currently in clinical trial for Pearson Syndrome and in Pre-clinical stage for Myelodysplastic Syndrome (MDS) indicating encouraging clinical and pre-clinical proof-of-concept for both primary mitochondrial diseases and age-related bone marrow failures. In Minovia we developed novel mitochondria-based biomarkers that allows us to stratify patients according to their "MitoScore". Minovia is establishing a novel aspect of cell therapy quality focusing on mitochondrial science, developing robust analytical methods to measure cellular mitochondrial function, as well as modalities to rescue mitochondrial dysfunction in different cell therapies.
Company Details
- Employees
- 27
- Founded
- -
- Address
- Haifa, Israel 3902603, Il
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://minoviatx.com
- Keywords
- Biotechnology, cell therapy, Rare diseases, Mitochondria, Mitochondrial Diseases, Mitochondrial Augmentation, Mitochondrial dysfunction.
- HQ
- Haifa, Israel
Minovia Therapeutics Questions
Minovia Therapeutics's website is http://minoviatx.com
Minovia Therapeutics's LinkedIn profile is https://www.linkedin.com/company/minoviatherapeutics
Minovia Therapeutics has
27 employees.
View email and phone details for 27
employees at Minovia Therapeutics.
Minovia Therapeutics's industry is
Biotechnology Research
Minovia Therapeutics's top competitors are
Nurexone Biologic (Otcqb:nrxbf) (Tsxv: Nrx) (Fse: J90),
Novocure,
Memed,
Biolinerx,
Cytoreason,
Bonus Biogroup,
Protalix Biotherapeutics,
Evogene,
Gsap,
Pluri.
Minovia Therapeutics's categories are Biotechnology Research
Minovia Therapeutics's founding year is 2012
